<DOC>
	<DOCNO>NCT01683331</DOCNO>
	<brief_summary>Specific Aim 1 : To determine clinical efficacy early initiation insulin therapy decrease incidence NODAT among de novo kidney transplant patient manifest post-transplant hyperglycemia first week transplantation . Hypothesis 1 : Early initiation insulin therapy protect beta-cell early stress relate surgery use high dos immunosuppressive medication , lead low incidence NODAT 1 2 year . Specific Aim 2 : To determine improvement overall glycemic control early initiation insulin therapy . Hypothesis 2 : Early initiation insulin therapy result great overall control glycemia compare standard care dietary counseling , life-style modification , oral hypoglycemic agent and/or insulin need 1 year . Specific Aim 3 : To determine improvement beta-cell function among patient assign early initiation insulin therapy one year post-transplantation . Hypothesis 3 : Early initiation insulin therapy protect beta-cell glucotoxicity post-transplant hyperglycemia preserve well beta-cell function 1 year .</brief_summary>
	<brief_title>A Clinical Trial Prevent New Onset Diabetes After Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Adult patient ( &gt; 18 year ) ESRD undergo kidney transplantation ; 2 . Standard triple immunosuppressive medication follow kidney transplantation include tacrolimus , mycophenolate moftile corticosteroid ; 3 . Capable understand study protocol give inform consent ; 1 . Type 1 2 DM either comorbidity cause ESRD ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Kidney transplant</keyword>
	<keyword>New onset diabetes</keyword>
	<keyword>Prevention</keyword>
	<keyword>Insulin</keyword>
</DOC>